Aug 30, 2008 4:27 AM ET | Site Changes | Help
Results 1 - 10 of 29 : 1 2 3 Next
Will Biopharma Acquisitions Never Cease?
Enough already! Give us poor, weary reporters a moment to rest.
What's better than a high-quality stock? One with the wind at its back!
Teva Gets a Taste of Its Own Medicine
Drug companies attack the generic-drug makers' patents.
5 Stocks Basking in the Summer Sun
These stocks are tops in the month of July.
Mylan Takes Generic Aim at Teva
Mylan licenses a generic version of Teva's MS drug, Copaxone.
The Anticoagulation Competition Bloodbath
Bayer and Johnson & Johnson give Sanofi's Lovenox another beating.
Wanted: FDA Approval -- Pronto
Teva and Amphastar have the courts on their side, but the FDA still stands in the way of a generic-drug launch.
The FDA gives the drugmaker a pathway to approval for a generic.
A nasty surprise hurts the drug developer's Q1 results.
Recent bearishness comes from more than just one analyst.
Legal Information © 1995 - 2008 The Motley Fool. All rights reserved.
Market Data provided by 
Terms & Conditions
RSS Headlines
Fool UK